Please assess the completion status of the following clinical trial:

Trial Title: Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Newly diagnosed histologically proven supratentorial glioblastoma (World Health Organization \[WHO\] Grade IV, including glioblastoma subtypes, for example, gliosarcoma). The histological diagnosis has to be obtained from a neurosurgical resection of the tumor or by an open biopsy (stereotactic biopsy is not allowed)~2. Tumor tissue specimens from the glioblastoma surgery or open biopsy (formalin-fixed paraffin-embedded) must be available for MGMT gene promoter status analysis and central pathology review~3. Proven unmethylated MGMT gene promoter status (that is, cut-off ratio less than (\<) 2 by means of applied test to determine MGMT gene promoter status)~4. Males or females greater than or equal to (\>=) 18 years of age~5. Interval of \>= 2 weeks but less than or equal to (=\<) 7 weeks after surgery or biopsy before first administration of study treatment~6. Available post-operative gadolinium-enhanced magnetic resonance imaging (Gd-MRI) performed within \< 48 hours after surgery~7. Stable or decreasing dose of steroids for \>= 5 days prior to randomization~8. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1~9. Has to meet 1 of the following recursive partitioning analysis (RPA) classifications:~   * Class III (Age \< 50 years and ECOG PS 0)~  * Class IV (meeting one of the following criteria: a) Age \< 50 years and ECOG PS 1 or b) Age \>= 50 years, underwent prior partial or total tumor resection, Mini Mental State Examination \[MMSE\] \>= 27)~  * Class V (meeting one of the following criteria: a) Age \>= 50 years and underwent prior partial or total tumor resection, MMSE \< 27 or b) Age \>= 50 years and underwent prior tumor biopsy only)~10. Other protocol defined inclusion criteria could apply~Exclusion Criteria:~1. Prior chemotherapy within the last 5 years~2. Prior RTX of the head (except for low dose RTX for tinea capitis)~3. Receiving concurrent investigational agents or has received an investigational agent within the past 30 days prior to the first dose of cilengitide~4. Prior systemic anti-angiogenic therapy~5. Placement of Gliadel® wafer at surgery~6. Planned surgery for other diseases~7. History of recent peptic ulcer disease (endoscopically proven gastric ulcer, duodenal ulcer, or esophageal ulcer) within 6 months of enrollment~8. History of malignancy. Subjects with curatively treated cervical carcinoma in situ or basal cell carcinoma of the skin, or subjects who have been free of other malignancies for \>= 5 years are eligible for this study~9. History of coagulation disorder associated with bleeding or recurrent thrombotic events~10. Clinically manifest myocardial insufficiency (New York Heart Association \[NYHA\] III, IV) or history of myocardial infarction during the past 6 months; or uncontrolled arterial hypertension~11. Inability to undergo Gd-MRI~12. Concurrent illness, including severe infection (for example, human immunodeficiency virus), which may jeopardize the ability of the subject to receive the procedures outlined in this protocol with reasonable safety~13. Subject is pregnant (positive serum beta human chorionic gonadotropin \[b-HCG\] test at screening) or is currently breast-feeding, anticipates becoming pregnant/impregnating their partner during the study or within 6 months after study participation, or subject does not agree to follow acceptable methods of birth control, such as hormonal contraception, intra-uterine pessar, condoms or sterilization, to avoid conception during the study and for at least 6 months after receiving the last dose of study treatment~14. Current alcohol dependence or drug abuse~15. Known hypersensitivity to the study treatment~16. Legal incapacity or limited legal capacity~17. Presence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule~18. Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such~19. Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cilengitide (2-times weekly) + Temozolomide + Radiotherapy (Type: EXPERIMENTAL): None
- Cilengitide (5-times weekly) + Temozolomide + Radiotherapy (Type: EXPERIMENTAL): None
- Temozolomide + Radiotherapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete